Ergothioneine prevents ovariectomy-induced osteoporosis by suppressing NF-κB/p65 signalling to attenuate osteoclastogenesis and bone marrow inflammation.

Gan Li, Qihang Fang, Zihao Lin, Chao Zhang, Chuan Gao, Daoyu Zhu, Haoyu Fang, Lingkang Dong, Peng Ding, Youshui Gao

Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. · pubmed

Paper

Abstract

Osteoporosis (OP), an age-related skeletal disorder, is characterized by excessive bone resorption driven by osteoclast overactivation, reactive oxygen species (ROS) accumulation, and chronic inflammation. Although the mitochondria-targeted antioxidant ergothioneine (EGT) has shown potential in regulating bone metabolism, its specific preventive mechanism in oestrogen-deficient osteoporosis remains unclear. Therefore, this study aimed to elucidate the preventive effects of EGT and its underlying mechanisms when administered early after ovariectomy.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Ergothioneine prevents ovariectomy-induced osteoporosis by suppressing NF-κB/p65 signalling. The study addresses a mechanism that could potentially mitigate age-related bone loss, which is a significant aspect of aging and longevity research.

Author of this paper? Send a correction.